title: Efficacy and safety of vinorelbine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients.
abstract: The aim of this study was to evaluate the efficacy and tolerance of vinorelbine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral or intravenous vinorelbine according to the pluridisciplinary tumor board's decision. Efficacy and safety outcomes were analyzed retrospectively. Twenty-three patients were included in the study. Sixteen patients (69%) had received at least two previous lines of chemotherapy. The disease control rate was 19%. The median progression-free survival was 2.6 months and the median overall survival was 3.4 months. The rate of grade 3-4 side effects was low (13%). Only one patient discontinued treatment because of side effects. Vinorelbine seems to be a well-tolerated regimen in heavily pretreated patients. However, this regimen does not seem to be efficient enough to be recommended.
authors.affiliation: Departments of aRadiation Oncology bHead and Neck Surgery, Tenon Hospital, HUEP, UPMC, Paris VI University, Paris, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Barth
authors.forename: Louise
authors.initials: L
authors.lastname: Naveau
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Touboul
authors.forename: Sophie
authors.initials: S
authors.lastname: Périé
authors.forename: Edith
authors.initials: E
authors.lastname: Bamogho
authors.forename: Sophie
authors.initials: S
authors.lastname: Haberer-Guillerm
authors.forename: Michel
authors.initials: M
authors.lastname: Schlienger
authors.forename: Jean
authors.initials: J
authors.lastname: Lacau St Guily
authors.forename: Florence
authors.initials: F
authors.lastname: Huguet
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012189:Retrospective Studies; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine